Full Press Release Details
Pharmaceuticals Achieves Chemical Manufacturing
include manufacturing of 3 registration lots for Mino-Lok
N.J., Sept. 22, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq:
CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced
that it has achieved a number of significant milestones over the past several weeks for
is an antibiotic lock solution being developed as an adjunctive therapy for patients with central line-associated bloodstream
infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). Mino-Lok contains three active drug substances
(minocycline, ethanol and EDTA) which are combined into two vials, MLT01 (minocycline) and MLT02 (ethanol and EDTA). Citius
has manufactured three registration lots of Mino-Lok using the commercial manufacturing process, which will be filed in the
planned New Drug Application (NDA). Citius has placed all registration lots on stability at the appropriate ICH (The
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) conditions to support
the NDA filing. Citius has also developed a new exclusive synthesis process for
disodium edetate ("EDTA"), a chelating agent which supplants heparin as the anti-clotting agent in
are applications to request permission to market a drug product in the U.S. for a specific use. Chemistry, manufacturing, and
controls (CMC) information is therefore submitted in the NDA to ensure product quality as it relates to the safety and efficacy
of the drug product.
typical drug approval contains one drug substance, so for all practical purposes our team has developed three products. Mino-Lok
is unique in many ways, this being one of them," said Myron Holubiak, Chief
Executive Officer of Citius. "It's important to know that we expect to be prepared to immediately move to validation/commercial
manufacturing upon the completion of our Phase 3 clinical trial and receiving the required FDA clearance."
Citius Pharmaceuticals, Inc.
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care
products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.
is an antibiotic lock solution being developed as an adjunctive therapy in patients with central line-associated bloodstream infections
(CLABSIs) or catheter-related bloodstream infections (CRBSIs). CLABSIs/CRBSIs are very serious, especially in cancer patients
receiving therapy through central venous catheters (CVCs) and in hemodialysis patients, for whom venous access presents a challenge.
There are currently no approved therapies for salvaging infected CVCs.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs
concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will,"
"anticipate," "estimate," "expect," "should," and "may" and other
words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are:
risks associated with conducting clinical trials and drug development; our dependence on third-party suppliers patent and intellectual
property matters; market and other conditions; our ability to attract, integrate, and retain key personnel; our need for substantial
additional funds; the risk of successfully negotiating within the option period a license agreement with Novellus, Inc. for our
planned NoveCite therapy for ARDS; the estimated markets for our product candidates and the acceptance thereof by any market;
risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating
to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates
and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our
SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on
which any such statement is based, except as required by law.
Vice President, Corporate Development
(O) 908-967-6677 x105